<DOC>
	<DOCNO>NCT01352494</DOCNO>
	<brief_summary>The purpose study assess response docetaxel gemcitabine neoadjuvant set woman locally advance breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy With Docetaxel Gemcitabine Locally Advanced Breast Cancer</brief_title>
	<detailed_description>Neoadjuvant chemotherapy standard patient locally advance breast cancer , method treatment extend patient earlier disease without affect treatment outcome . This single arm , multicenter phase II study design evaluate response rate , toxicity , progression free survival tumor control rate docetaxel gemcitabine neoadjuvant set locally advance breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Women age : 20~70 year 2 . World Health Organization ( WHO ) ( Eastern Cooperative Oncology Group [ ECOG ] ) performance status 02 3 . Patients measurable lesion assess image use RECIST ( Response Evaluation Criteria In Solid Tumor ) guideline 4 . Have give write informed consent available prolong followup 1 . Patients previous chemotherapy recurrent breast cancer 2 . Breast cancer recurrence within 12 month taxane treatment 3 . Her2/neu expression breast cancer 4 . Patients malignancy ( breast cancer ) within last 5 year , except adequately treat situ carcinoma cervix basal cell , squamous cell carcinoma skin . 5 . Brain metastasis 6. uncontrolled infection , medically uncontrollable heart disease 7. serious medical illness prior malignancy 8 . Pregnant lactate woman exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>locally advanced breast cancer</keyword>
	<keyword>docetaxel</keyword>
	<keyword>gemcitabine</keyword>
</DOC>